Mifepristone ruling keeps mail access as FDA review looms

A federal mifepristone ruling is allowing abortion pills to continue being sent by mail across the United States—for now—while regulators review the drug’s safety and legal challenges move forward.

David Joseph declined to block current rules that permit mailing prescriptions for mifepristone, dealing a temporary setback to efforts by Liz Murrill to restrict access in states where abortion is banned.

However, the judge made clear that the decision is not final. He ordered the Food and Drug Administration to complete an ongoing review of the drug and report back within six months, signaling that the outcome could still change.

Louisiana officials argue that allowing abortion pills to be prescribed via telehealth and delivered by mail undermines state abortion bans. Murrill said she plans to appeal, even as the court acknowledged the state may ultimately succeed in its case.

The mifepristone ruling comes amid a broader national conflict over abortion access following the end of Roe v. Wade in 2022. Since then, states have taken sharply different approaches, with some banning abortion entirely and others enacting laws to protect access, including through telehealth services.

Medication abortion—typically involving mifepristone and a second drug—has become central to that divide. Studies show that telehealth prescriptions have surged in recent years, particularly in states where abortion is restricted.

Supporters of access argue that mailing the medication expands care for patients who might otherwise face significant barriers. Critics, including Louisiana officials, warn that the lack of in-person oversight could increase risks, including cases of coercion.

Advocacy groups stress that the legal fight is far from over. Planned Parenthood leaders said the ruling offers only temporary relief and warned that abortion access remains under sustained political and legal pressure.

For now, the mifepristone ruling preserves the status quo. But with the FDA review underway and appeals expected, the future of mail access to abortion pills remains uncertain—and likely headed for further court battles.